CA
TARS icon

Cliff Asness’s Tarsus Pharmaceuticals TARS Stock Holding History

Cliff Asness’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Buy
42,003
+11,550
+38% +$738K ﹤0.01% 2435
2026
Q1 		$2.14M Buy
30,453
+4,534
+17% +$317K ﹤0.01% 2304
2025
Q4 		$2.12M Sell
25,919
-11,176
-30% -$834K ﹤0.01% 2097
2025
Q3 		$2.2M Sell
37,095
-16,473
-31% -$811K ﹤0.01% 1921
2025
Q2 		$2.17M Buy
53,568
+37,344
+230% +$1.68M ﹤0.01% 1725
2025
Q1 		$833K Hold
16,224
– – ﹤0.01% 2138
2024
Q4 		$898K Sell
16,224
-3,696
-19% -$168K ﹤0.01% 1938
2024
Q3 		$655K Buy
19,920
+12,427
+166% +$349K ﹤0.01% 2056
2024
Q2 		$204K Sell
7,493
-2,702
-27% -$90.9K ﹤0.01% 2419
2024
Q1 		$371K Buy
+10,195
New +$300K ﹤0.01% 2070

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cliff Asness's TARS Position: Q2 2026 in Review

Cliff Asness increased its Tarsus Pharmaceuticals (TARS) stake by 38% in Q2 2026, buying an estimated $738K and bringing the position to 42,003 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2435.

Cliff Asness first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Cliff Asness held 42,003 shares of Tarsus Pharmaceuticals worth $2.64M as of Q2 2026.
  • Cliff Asness bought 11,550 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $738K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2435 holding.
  • Cliff Asness first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.